| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test | Frank Vinluan | 09/10/20 | San Francisco |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study | Sarah de Crescenzo | 03/30/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK | Frank Vinluan | 02/27/20 | New York |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come | Frank Vinluan | 02/10/20 | New York |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines | Sarah de Crescenzo | 12/24/19 | National |
| Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More | Frank Vinluan | 11/01/19 | National |
| Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More | Frank Vinluan | 10/18/19 | National |
| Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More | Alex Lash | 09/20/19 | National |
| Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market | Mike Ward | 09/16/19 | National |
| Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs | Frank Vinluan | 08/16/19 | New York |
| Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache | Frank Vinluan | 06/04/19 | Indiana |
| SMA, Migraine Data Lead Neuro Highlights from AAN Meeting | Ben Fidler | 05/07/19 | National |
| Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More | Alex Lash | 05/03/19 | National |
| At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments | Frank Vinluan | 05/03/19 | National |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache | Frank Vinluan | 04/23/19 | New York |
| Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More | Frank Vinluan | 04/05/19 | National |
| Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More | Frank Vinluan | 11/16/18 | National |
| Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals | Frank Vinluan | 10/17/18 | National |
| Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More | Frank Vinluan | 10/05/18 | National |
| Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines | Frank Vinluan | 09/28/18 | Indiana |
| Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s | Frank Vinluan | 09/14/18 | National |
| Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More | Frank Vinluan | 06/22/18 | National |
| Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches | Frank Vinluan | 06/15/18 | National |
